Patent · US Active

Compounds for the inhibition of integrins and use thereof

US8927534B2 · kind B2 · utility

2Cited by

3References

4Claims

0Family size

Assignee

Shire Orphan Therapies GmbH · DE

Inventors

Gunther Zischinsky · Berlin, DE
Roland Stragies · Berlin, DE
Frank Osterkamp · Berlin, DE
Dirk Scharn · Wien, AT
Gerd Hummel · Berlin, DE
Holger Kalkhof · Berlin, DE
Grit Zahn · Berlin, DE
Doerte Vossmeyer · Berlin, DE
Claudia Christner-Albrecht · Berlin, DE
Ulrich Reineke · Berlin, DE

Key dates

Filing date	Jan 31, 2007
Grant date	Jan 6, 2015
Priority date	—
Expiry date	Feb 11, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D471/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention is related to a compound of formula (I), wherein A is a nonaromatic heterocyclic ring, Ar is either absent or phenylene; Ψ is a radical of formula (II), R2 is a hydrophobic moiety; and G is a radical containing one or more moieties selected from the group consisting of NH, OH and a basic moiety. The compounds are inhibitors of integrins, especially antagonists of the fibronectin receptor alpha5beta1, useful as anti-angiogenic agents.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.